SEC Form SC 13G/A filed

1	Names of Reporting Persons.   DME Advisors LP
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a)            [ ]
	(b)            [ ]
3	SEC Use Only
4	Citizenship or Place of Organization.   Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5  Sole Voting Power   0 shares
		6  Shared Voting Power   191,900 shares
		7  Sole Dispositive Power   0 shares
		8  Shared Dispositive Power   191,900 shares
9	Aggregate Amount Beneficially Owned by Each Reporting Person   191,900 shares
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ]
11	Percent of Class Represented by Amount in Row (9)   0.8%
12	Type of Reporting Person (See Instructions)   IA

This Amendment No. 1 (the “Amendment”) to Schedule 13G relating to common stock, par value $0.0001 per share (“Common Stock”) of NeuBase Therapeutics, Inc., a Delaware corporation (the “Company” or the “Issuer”), is being filed with the Securities and Exchange Commission (the “SEC”) as an amendment to the Schedule 13G filed with the SEC on July 16, 2019.  This Amendment is being filed on behalf of Greenlight Capital, Inc., a Delaware corporation (“Greenlight Inc.”), DME Capital Management, LP, a Delaware limited partnership (“DME CM”), DME Advisors, LP, a Delaware limited partnership (“DME Advisors”), DME Advisors GP, LLC, a Delaware limited liability company (“DME GP” and together with Greenlight Inc., DME CM and DME Advisors, “Greenlight”), and Mr. David Einhorn, the principal of Greenlight (collectively with Greenlight, the “Reporting Persons”).

This Amendment relates to Common Stock of the Issuer held by Greenlight for the account of private investment funds (the “Greenlight Accounts”) for which Greenlight acts as investment advisor or manages a portfolio (or serves as general partner of the investment advisor or manager of the portfolio) and with respect to which Mr. Einhorn may be deemed to have indirect investment and/or voting power as the principal of Greenlight and other affiliated entities.  DME GP is the general partner of DME CM.

The filing of this Schedule 13G shall not be construed as an admission that any of the Reporting Persons is for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, the beneficial owner of any of the shares of Common Stock reported herein.  Pursuant to Rule 13d-4, each of the Reporting Persons disclaims all such beneficial ownership except to the extent of its pecuniary interest in any shares of Common Stock, if applicable.

This Amendment is being filed to amend and restate Item 4.

Greenlight Inc. may be deemed the beneficial owner of 945,196 shares of Common Stock.

DME CM may be deemed the beneficial owner of 889,931 shares of Common Stock.

DME Advisors may be deemed the beneficial owner of 191,900 shares of Common Stock.

DME GP may be deemed the beneficial owner of 1,081,831 shares of Common Stock.

David Einhorn may be deemed the beneficial owner of 2,027,027 shares of Common Stock.

The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.  The percentages reported herein are calculated on the basis of a statement in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on December 23, 2020, that there were 23,177,591 shares of Common Stock outstanding as of December 21, 2020.

Date:

February 16, 2021